{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:55:42Z","timestamp":1794318942431,"version":"4.9.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.ygyno.2010.12.362","type":"journal-article","created":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T04:24:00Z","timestamp":1296102240000},"page":"273-279","source":"Crossref","is-referenced-by-count":167,"title":["A phase II, single-arm study of the anti-\u03b15\u03b21 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer"],"prefix":"10.1016","volume":"121","author":[{"given":"Katherine M.","family":"Bell-McGuinn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffan N.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Barve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Lengyel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rameshraja","family":"Palaparthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kye","family":"Gilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artemios","family":"Vassos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"McAuliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Weymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2010.12.362_bb0005","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/01.ATV.0000016045.93313.F2","article-title":"Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies","volume":"22","author":"Francis","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0010","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1091\/mbc.E03-07-0528","article-title":"Fibronectin matrix assembly regulates alpha5beta1-mediated cell cohesion","volume":"15","author":"Robinson","year":"2004","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0015","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1172\/JCI0214268","article-title":"Inhibition of endothelial cell survival and angiogenesis by protein kinase A","volume":"110","author":"Kim","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0020","first-page":"273","article-title":"Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent","volume":"5","author":"Ramakrishnan","year":"2006","journal-title":"J Exp Ther Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0025","first-page":"562","article-title":"Inhibitors of angiogenesis in therapy of ovarian cancers","volume":"25","author":"Markowska","year":"2004","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0030","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-07-5167","article-title":"Loss of E-cadherin promotes ovarian cancer metastasis via \u03b15-integrin, which is a therapeutic target","volume":"68","author":"Sawada","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0304-3835(95)03743-G","article-title":"Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis","volume":"91","author":"Gardner","year":"1995","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0040","doi-asserted-by":"crossref","first-page":"7924","DOI":"10.1158\/1078-0432.CCR-08-0378","article-title":"Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study","volume":"14","author":"Ricart","year":"2008","journal-title":"Clin Can Res"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0050","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0060","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0065","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0070","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0075","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/01.AOG.0000220516.34053.48","article-title":"Diagnosis and management of epithelial ovarian cancer","volume":"107","author":"Bhoola","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0080","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","article-title":"Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials","volume":"59","author":"Blackledge","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0085","first-page":"798","article-title":"Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin based therapy","volume":"73","author":"Gershenson","year":"1989","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0090","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","article-title":"Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0095","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0100","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2005.12.017","article-title":"Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum\u2013taxane therapy: a phase II Austrian AGO study","volume":"102","author":"Petru","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0110","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0115","first-page":"25","article-title":"Phase I\/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma","author":"Stupp","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00280-009-1023-8","article-title":"Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-\u03b15\u03b21 integrin monoclonal antibody (volociximab) in cancer patients","volume":"65","author":"Ng","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2008.09.021","article-title":"Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer","volume":"112","author":"Fan","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0130","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/ijc.23717","article-title":"Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands","volume":"123","author":"He","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0135","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/nm1101-1194","article-title":"Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth","volume":"7","author":"Lyden","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0140","first-page":"27","article-title":"The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer","volume":"1796","author":"Bertolini","year":"2009","journal-title":"Biochem Bipphys Acta"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0145","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1126\/science.1150224","article-title":"Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis","volume":"319","author":"Gao","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0150","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1126\/science.1127592","article-title":"Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors","volume":"22","author":"Shaked","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0160","first-page":"27","article-title":"Safety and early efficacy results from a phase I study of volociximab (V) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with advanced non small cell lung cancer (NSCLC)","author":"Besse","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0165","first-page":"26","article-title":"A multi-center phase II study of volociximab in patients with relapsed metastatic melanoma","author":"Stephenson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.12.362_bb0170","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ccr.2008.08.001","article-title":"Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents","volume":"14","author":"Shaked","year":"2008","journal-title":"Cancer Cell"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810012692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810012692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T00:39:07Z","timestamp":1559954347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825810012692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0090825810012692"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.12.362","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}